About Importin subunit alpha-1
Importin subunit alpha-1 (KPNA2) is a protein
from Homo sapiens identified by UniProt accession
P52292, 529 residues long.
MolForge cross-references it against 0 known binders and
282 disease associations.
Target properties
| Protein name | Importin subunit alpha-1 |
| UniProt accession | P52292 |
| Gene | KPNA2 |
| Organism | Homo sapiens |
| Length | 529 residues |
| Molecular weight | — |
| EC numbers | — |
| Target class | UNCLASSIFIED |
| Subcellular location | — |
| Keywords | — |
Druggability
Target tractability assessment (Open Targets + pocket analysis). No approved drug
| Druggability tier | MEDIUM |
| Druggability score | — |
| Pocket score | — |
| Max clinical phase | — |
Disease associations (282)
Diseases linked to this target (Open Targets).
- influenza · score 0.46
- severe acute respiratory syndrome · score 0.46
- COVID-19 · score 0.37
- FEV/FVC ratio · score 0.35
- eosinophil count · score 0.35
- peripheral arterial disease · score 0.33
- loneliness measurement · score 0.32
- eosinophil percentage of leukocytes · score 0.30
- lymphocyte count · score 0.29
- heel bone mineral density · score 0.27
3D Structure (1)
Experimental (PDB) and predicted (AlphaFold) structures for this protein.
| Structure | Source | Method | Mean pLDDT | Resolution (Å) |
| AF-P52292-F1 | alphafold | PREDICTED | 86.52 | — |
Amino-acid sequence (529 residues)
MSTNENANTP AARLHRFKNK GKDSTEMRRR RIEVNVELRK AKKDDQMLKR RNVSSFPDDA TSPLQENRNN QGTVNWSVDD IVKGINSSNV ENQLQATQAA RKLLSREKQP PIDNIIRAGL IPKFVSFLGR TDCSPIQFES AWALTNIASG TSEQTKAVVD GGAIPAFISL LASPHAHISE QAVWALGNIA GDGSVFRDLV IKYGAVDPLL ALLAVPDMSS LACGYLRNLT WTLSNLCRNK NPAPPIDAVE QILPTLVRLL HHDDPEVLAD TCWAISYLTD GPNERIGMVV KTGVVPQLVK LLGASELPIV TPALRAIGNI VTGTDEQTQV VIDAGALAVF PSLLTNPKTN IQKEATWTMS NITAGRQDQI QQVVNHGLVP FLVSVLSKAD FKTQKEAVWA VTNYTSGGTV EQIVYLVHCG IIEPLMNLLT AKDTKIILVI LDAISNIFQA AEKLGETEKL SIMIEECGGL DKIEALQNHE NESVYKASLS LIEKYFSVEE EEDQNVVPET TSEGYTFQVQ DGAPGTFNF
Explore Importin subunit alpha-1 with MolForge
Find binders, run structure-based screening, and map this target across
diseases and approved drugs with our AI-powered platform.
Browse all targets